Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer
NCT ID: NCT00907504
Last Updated: 2014-06-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2010-07-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
NCT00254904
Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
NCT00560573
Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
NCT00530634
Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin
NCT00055965
Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
NCT00103051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CP-751,871 + Gemcitabine + Cisplatin
investigational arm
CP-751,871
CP-751,871 20mg/kg every 3 weeks
Cisplatin
Cisplatin 80 mg/m2 every 3 weeks
Gemcitabine
Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
Gemcitabine + Cisplatin
standard of care
Cisplatin
Cisplatin 80 mg/m2 every 3 weeks
Gemcitabine
Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-751,871
CP-751,871 20mg/kg every 3 weeks
Cisplatin
Cisplatin 80 mg/m2 every 3 weeks
Gemcitabine
Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
Cisplatin
Cisplatin 80 mg/m2 every 3 weeks
Gemcitabine
Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female \> 18 years
* Eastern Oncology Cooperative Group (ECOG) Performance Status (PS) 0 or 1
* Adequate organ function
Exclusion Criteria
* Pregnant female;
* Symptomatic Central Nervous System (CNS) metastasis, requirement for chronic corticosteroids.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A4021017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.